Clinical Trial Update: A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection [Phase 1]

View source ↗

Summary

A Phase 1 pilot study assessing the safety of a 3-week sitagliptin treatment in patients with hepatocellular carcinoma undergoing liver resection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sitagliptin (sitagliptin)

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Hepato Carcinoma | Phase 1 | Status: COMPLETED